imatinib mesylate has been researched along with Musculoskeletal Pain in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Breccia, M; Colafigli, G; Di Prima, A; Efficace, F; Foà, R; Martelli, M; Scalzulli, E | 1 |
| Alimena, G; Baccarani, M; Baratè, C; Bergamaschi, M; Breccia, M; Cottone, F; Dabusti, M; Deliliers, GL; Di Lorenzo, R; Efficace, F; Fava, C; Leoni, P; Levato, L; Luciano, L; Mandelli, F; Martino, B; Rambaldi, A; Rosti, G; Sica, S; Simula, MP; Specchia, G; Stagno, F; Turri, D; Veneri, D; Vignetti, M | 1 |
| Gressett Ussery, SM; Heym, KM; Philpot, LM; Trinkman, H | 1 |
1 review(s) available for imatinib mesylate and Musculoskeletal Pain
| Article | Year |
|---|---|
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Monitoring; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Meta-Analysis as Topic; Musculoskeletal Pain; Observational Studies as Topic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; RNA, Messenger; RNA, Neoplasm; Substance Withdrawal Syndrome; Withholding Treatment | 2020 |
2 other study(ies) available for imatinib mesylate and Musculoskeletal Pain
| Article | Year |
|---|---|
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Fatigue Syndrome, Chronic; Female; Health Surveys; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Muscle Cramp; Musculoskeletal Pain; Piperazines; Pyrimidines; Quality of Life; Social Behavior; Young Adult | 2013 |
Nonhematologic toxicity of imatinib mesylate in pediatric patients with chronic myelogenous leukemia: a predominance of musculoskeletal pain.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Musculoskeletal Pain; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Young Adult | 2015 |